Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT05602103 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies

Start date: November 5, 2024
Phase:
Study type: Observational

Little is known about cancer therapy-related cardiac dysfunction occuring in children treated by anticancer drugs for malignancies. Here the investigators use VigiBase (http://www.vigiaccess.org/), the World Health Organization (WHO) database of individual safety case reports, to identify and describe cases of cancer therapy-related cardiac dysfunction associated with anticancer drugs.

NCT ID: NCT05600010 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Detection of Microplastics in Cardiac Surgery Patients

Start date: November 1, 2022
Phase:
Study type: Observational

The exponential growth in plastic production/use translates into a parallel increase in environmental plastic waste, which is constantly degraded into microplastics and nanoplastics. Information on the effects of microplastics on human health is still preliminary. Cardiac surgery patients is a population high exposed to plastics. This observational study will obtain biological samples of cardiac surgery patients as a reference and vulnerable group of individuals highly exposed to microplastics and potentially more susceptible. The objective of this research is to be able to detect microplastics on blood and operation samples of cardiac surgery patients as well as their potential genotoxic and immunological damage.

NCT ID: NCT05598879 Recruiting - Breast Cancer Clinical Trials

Global Cardio Oncology Registry

G-COR
Start date: July 1, 2022
Phase:
Study type: Observational [Patient Registry]

G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.

NCT ID: NCT05598567 Completed - Cardiac Event Clinical Trials

Hemodynamic Parameters and Cardiac Enzyme Levels in Patients Undergoing General Anesthesia

Start date: June 6, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about the effects of total intravenous general anesthesia with target controlled infusion and sevoflurane based balanced general anesthesia on hemodynamic parameters and cardiac enzyme levels in patients undergoing total abdominal hysterectomy.

NCT ID: NCT05598385 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Groin Complications in Open vs. Percutaneous Peripheral Cannulation in Minimally Invasive Cardiac Surgery

ProGlide-II
Start date: April 14, 2024
Phase: N/A
Study type: Interventional

The aim of this randomized trial is to investigate the groin complications in open vs percutaneous peripheral cannulation for cardiopulmonary bypass in minimally invasive cardiac surgery

NCT ID: NCT05590780 Completed - Clinical trials for Cardiovascular Diseases

Analysis of Cell-free DNA (cfDNA) During Periodontitis

Start date: November 1, 2019
Phase:
Study type: Observational

The purpose of this study was to examine the association between circulating cfDNA concentration and CVD risk in patients with periodontitis, CVD, and periodontitis plus CVD. In addition, the secondary objective was to identify, among other confounders, the impact of periodontitis and cardiovascular disease as potential significant predictors of circulating cfDNA levels in the enrolled population.

NCT ID: NCT05589779 Not yet recruiting - Asthma Clinical Trials

Relationship Between Cardiovascular Disease in Asthma and Eosinophil Subtypes and Biomarkers of Bronchial Remodeling.

Start date: April 1, 2023
Phase:
Study type: Observational

To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease.

NCT ID: NCT05584943 Completed - Clinical trials for Cardiovascular Diseases

Kinetics of cEVs Over the 24-hour Dosing Interval After Low-dose Aspirin Administration

Start date: September 21, 2015
Phase:
Study type: Observational

Extracellular vesicles (EVs) are small vesicles deriving from all cell types during cell activation, involved in transcellular communication, and regarded as predictors of vascular damage and of cardiovascular events. The investigators will test the hypothesis that, in patients on chronic low-dose aspirin treatment for cardiovascular prevention, aspirin may affect the release of EVs within the 24 hours interval.

NCT ID: NCT05581368 Recruiting - Clinical trials for Cardiovascular Diseases

Studying the Effects of Cannabis on Vasculature

SECV
Start date: December 1, 2023
Phase:
Study type: Observational

Cannabis is commonly used globally. It is associated with psychiatric problems, but the effects on the cardiovascular system are unclear. In this project, the investigators plan to study the effects of cannabis on the cardiovascular system. This will be done by using a non-invasive test to measure blood vessel function and by using blood samples to measure inflammation. As a control for this project, the investigators would like to test the blood vessel function and inflammation levels of participants who do not use cannabis. This study will provide important information on the long term cardiovascular effects of cannabis.

NCT ID: NCT05581303 Active, not recruiting - Clinical trials for Atherosclerotic Cardiovascular Disease

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Start date: December 14, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).